Description
Fluoxymesterone (Halotestin, Halo, Stenox) is a fluorinated methyltestosterone derivative with 17α-methyl group and 11β-hydroxyl group. The fluoro modification at C9 makes the substance extremely potent and resistant to metabolic breakdown.
Per study reports Halotestin binds with high affinity to the androgen receptor with values substantially above testosterone. The substance doesn’t aromatize to estradiol, excluding water retention. The pharmacology profile is sharply androgenic with low anabolic component - Halotestin acts primarily on strength, aggression and subjective hardness without significant mass gain.
In recreational research practice Halotestin has two clear use cases: pre-contest bodybuilding research in the last 2-4 weeks before competition (for dry hardness and elevated aggression research profile) and powerlifting meet days (strength spike without weight gain).
Pharmacokinetically orally bioavailable with about 9-hour half-life. Bioavailability good due to 17α-methyl group.
Known effects in studies: extremely high hepatotoxicity - Halotestin is among the most hepatotoxic anabolics overall. ALT/AST elevations are regularly documented under Halo cycles; cholestasis research reports are more frequent than with other orals. Cycle duration is limited to 2-4 weeks in practice.
Further effects: pronounced aggression elevation in recreational research reporting, hypertension, unfavorable lipid profile with massive HDL drop.
Halotestin is on the WADA banned list.
You can order Fluoxymesterone as oral tablets in one bottle with 10mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Fluoxymesterone is among the most aggressive and most hepatotoxic oral anabolics overall and therefore sits clearly in the upper range of the risk scale. The effects documented in the literature are pronounced and primarily affect the liver.
Documented in studies and the user literature:
- Extremely high liver strain: Halotestin is among the most hepatotoxic 17α-methyl steroids. ALT/AST elevations are regularly documented. Cholestasis reports are more frequent than with other orals.
- Lipid profile: studies describe an unfavorable lipid profile with a massive HDL drop.
- Aggression and blood pressure: pronounced aggression elevation and hypertension are documented in the user literature.
- Suppression of natural production: as a strongly androgenic compound, suppression of the HPG axis is established in the literature.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Fluoxymesterone in the treatment of advanced breast cancer - Cancer 1957, Kennedy: Classic oncology study on use in metastatic breast cancer.
- Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer - A randomized study - Breast Cancer Research and Treatment 1988, Swain et al: Randomized comparison of hormone combination therapies in metastatic breast cancer.
- Antitumor Efficacy of Fluoxymesterone - Archives of Internal Medicine 1961, Lowe et al: Early clinical study on antitumor efficacy.
- The Anabolic Androgenic Steroid Fluoxymesterone Inhibits 11-Hydroxysteroid Dehydrogenase 2-Dependent Glucocorticoid Inactivation - Toxicological Sciences 2012, Furstenberger et al: Mechanism study on glucocorticoid inactivation inhibition.
- Ataxia Caused by Fluoxymesterone Therapy in Breast Cancer - Archives of Internal Medicine 1981, Agrawal: Case report on neurological side effect under fluoxymesterone.
